{"product_id":"society-of-hematologic-oncology-tenth-annual-meeting-2022","title":"Society of Hematologic Oncology Tenth Annual Meeting 2022","description":"\u003ch3\u003eSociety of Hematologic Oncology Tenth Annual Meeting 2022\u003c\/h3\u003e\n\u003cstrong\u003e Include: 122 videos, size: 8.62 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: hemtologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cbr\u003e\u003cbr\u003eThe Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) took place \u003cstrong\u003eSeptember 28 – October 1, 2022\u003c\/strong\u003e  at the Hilton Americas, 1600 Lamar St, Houston, and on the SOHO Attendee Hub, with attendance from nearly 2,200 hematologic oncology professionals. Approximately 1600 gathered onsite in Houston. In addition, \u003cstrong\u003e122 Experts\u003c\/strong\u003e delivered 152 cutting-edge presentations during the meeting. .\u003cbr\u003e\u003cp class=\"\"\u003eSOHO members and meeting attendees have access to over 150 on-demand educational presentations from the 2022 Annual Meeting as well as speakers’ slides, abstracts, posters and other items. Organized by its founders and world class committees, SOHO is the only worldwide society specific to the field of hematologic malignancies. SOHO is the premier meeting that focuses specifically on new advances and practical clinical applications in the field of hematologic malignancies. The speakers are a multidisciplinary group of internationally recognized experts that represent the spectrum of these diseases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003eThe Society of Hematologic Oncology Tenth Annual Meeting 2022 was designed for a wide range of healthcare professionals interested in hematologic oncology. The target audience included:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003ePhysicians\u003c\/li\u003e\n\u003cli\u003eFellows\u003c\/li\u003e\n\u003cli\u003eNurses\u003c\/li\u003e\n\u003cli\u003ePhysician assistants\u003c\/li\u003e\n\u003cli\u003ePharmacists\u003c\/li\u003e\n\u003cli\u003eStudents interested in Hematology Oncology, Medical Oncology, and Internal Medicine.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAdditional Agents for R R MM – How Do Will They Fit.ts\u003cbr\u003eAdvances in ALL Diagnosis and Treatment – The NOPHO Experience.ts\u003cbr\u003eAdvances in the Treatment of NK T Cell Lymphoma.ts\u003cbr\u003eAGILE – A Phase 3, Global, Randomized, Double-Blind Study of Ivo + Aza vs. Placebo + Aza in Newly Diagnosed AML With an IDH1 Mutation.ts\u003cbr\u003eAllogeneic CAR T-Cells in ALL.ts\u003cbr\u003eAML DEBATE- Is MRD More Prognostic Than Initial Presentation Characteristics. CON.ts\u003cbr\u003eAML DEBATE- Is MRD More Prognostic Than Initial Presentation Characteristics. PRO.ts\u003cbr\u003eAmyloidosis – Update and How To Use Novel Agents.ts\u003cbr\u003eApproach to ALL in the Elderly.ts\u003cbr\u003eApproach to Ph-Like ALL.ts\u003cbr\u003eApproaches to and Use of MRD in ALL.ts\u003cbr\u003eAsciminib or Ponatinib for Multiresistant CML Patients.ts\u003cbr\u003eAssessment and Management of TKI-Related AOEs in CML.ts\u003cbr\u003eBasis for Targeting the Microenvironment in Hodgkin Lymphoma.ts\u003cbr\u003eBCL-2 Inhibition in MDS.ts\u003cbr\u003eBCL2i in CLL.ts\u003cbr\u003eBeyond TKI Therapy in CML.ts\u003cbr\u003eBiology and Treatment of LGL Leukemia.ts\u003cbr\u003eBispecific T-Cell Engagers – Early Data and Where Will We Use Them..ts\u003cbr\u003eBlinatumomab in Pediatric ALL.ts\u003cbr\u003eCamidanlumab Tesirine – Updated Efficacy and Safety in Patients With RR cHL.ts\u003cbr\u003eCan Potential Disease Modifying Agents Change the Indication for Transplant in MPN.ts\u003cbr\u003eCAR T-Cell in MM – When To Use Now, Where Are We Going..ts\u003cbr\u003eCAR T-Cell Therapy in Hodgkin Lymphoma.ts\u003cbr\u003eCAR T-Cells in Indolent B-Cell Lymphomas.ts\u003cbr\u003eCertain Patients With ALL Still Need a Transplant.ts\u003cbr\u003eChallenging Cases in Rare T-Cell Lymphomas.ts\u003cbr\u003eCharacteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years.ts\u003cbr\u003eChildhood CML.ts\u003cbr\u003eChoosing CAR T-Cell Therapy vs. ASCT in RR Aggressive B-cell Lymphoma.ts\u003cbr\u003eClinical Significance of B-Cell Receptor Stereotypy in CLL.ts\u003cbr\u003eCLL – Real World Data With Small Molecules.ts\u003cbr\u003eCLL DEBATE- Combination Small Molecules vs. Sequencing in CLL – Pro Combination Small Molecules.ts\u003cbr\u003eCLL DEBATE- How Many Drugs Are Needed in 1L CLL..ts\u003cbr\u003eCNS Prophylaxis in DLBCL.ts\u003cbr\u003eCorrelation of TRBC1 by Flow Cytometry With Molecular T-Cell Receptor Clonality for the Investigation of T-Cell Lymphocytosis.ts\u003cbr\u003eCost-Effectiveness of Polatuzumab Vedotin in Previously Untreated DLBCL.ts\u003cbr\u003eCovalent BTK Inhibitors – How Do They Compare in CLL.ts\u003cbr\u003eCytopenic Myelofibrosis.ts\u003cbr\u003eDEBATE- Bispecific Antibodies vs. CAR-T for R R MM – Defending Bispecific Antibodies.ts\u003cbr\u003eDEBATE- Bispecific Antibodies vs. CAR-T for R R MM – Pro CAR-T.ts\u003cbr\u003eDEBATE- CAR T-Cell vs. AUTO HCT for RR DLBCL – Pro AUTO HCT.ts\u003cbr\u003eDEBATE- CAR T-Cell vs. AUTO HCT for RR DLBCL – Pro CAR T-Cell.ts\u003cbr\u003eDREAMM-6 Arm-A Interim Analysis – Safety and Clinical Activity of Belantamab Mafodotin With Len + Dex in RR MM.ts\u003cbr\u003eDual Targeted CAR T-Cells for ALL.ts\u003cbr\u003eEarly Intervention in Myelofibrosis.ts\u003cbr\u003eEmerging CAR T-Cell Therapy Approaches in AML.ts\u003cbr\u003eEmerging Treatment Options for MCL.ts\u003cbr\u003eFLT3-Mutated AML – Triplet vs. Doublet Therapy.ts\u003cbr\u003eFrom Bench to Bedside – A Translational Scientist’s Perspective on How to Transform PTCL Outcome.ts\u003cbr\u003eFuture Role of Bispecific Antibodies in the Treatment of Follicular Lymphoma.ts\u003cbr\u003eGLOW Study – First Prospective Data on MRD Outcomes After Fixed-Duration Ibr+Ven vs. Clb+O for 1L Treatment of CLL in Older Adult or Unfit Patients.ts\u003cbr\u003eHas R-CHOP Really Been Replaced as Initial Therapy of DLBCL..ts\u003cbr\u003eHow Do We Overcome Resistance to Venetoclax in AML.ts\u003cbr\u003eImmune Therapy Approaches in MDS.ts\u003cbr\u003eImmunotherapeutic Options for Patients With MCL Who Progress on BTK Inhibitors.ts\u003cbr\u003eImmunotherapy – The Way Forward to Maximize TFR in CML..ts\u003cbr\u003eIntegrating Novel Agents Into the Management of Cutaneous T-cell Lymphoma.ts\u003cbr\u003eIs it Time to Recognize the Biological Heterogeneity of MCL.ts\u003cbr\u003eIs the Future of AML Therapy All Oral..ts\u003cbr\u003eIs TP53-Mutated AML the Same Disease as TP53-Mutated MDS..ts\u003cbr\u003eLong-Term Outcomes After Haplo-SCT for Hematologic Malignancies.ts\u003cbr\u003eMagrolimab + Azacitidine for Patients With Untreated HR MDS – 5F9005 Phase 1b Study Results.ts\u003cbr\u003eManagement of Ph+ ALL in 2022.ts\u003cbr\u003eManagement of Prefibrotic Myelofibrosis.ts\u003cbr\u003eManaging the Elderly Patient With Aggressive B-cell Lymphoma in The Modern Era.ts\u003cbr\u003eMenin Inhibitors in AML.ts\u003cbr\u003eMM DEBATE- Auto + Maintenance Should Remain SoC in MM.ts\u003cbr\u003eMM DEBATE- CAR T-Cell Maintenance Will Replace Auto in MM.ts\u003cbr\u003eMM Frontline Therapy for Transplant-Eligible Ineligible Patients- How to Choose Agents.ts\u003cbr\u003eMolecular Classification of MDS.ts\u003cbr\u003eMRD Assessments in MM – Should We. When. Why..ts\u003cbr\u003eNew BTKi in CLL.ts\u003cbr\u003eNext Questions CML.ts\u003cbr\u003eNext Questions for MM in the Coming 5-10 Years.ts\u003cbr\u003eNext Questions- ALL.ts\u003cbr\u003eNext Questions- AML.ts\u003cbr\u003eNext Questions- Cellular Therapy.ts\u003cbr\u003eNext Questions- CLL.ts\u003cbr\u003eNext Questions- Follicular Lymphoma.ts\u003cbr\u003eNext Questions- Hodgkin Lymphoma.ts\u003cbr\u003eNext Questions- Mantle Cell Lymphoma.ts\u003cbr\u003eNext Questions- Myelodysplastic Syndromes.ts\u003cbr\u003eNext Questions- Myeloproliferative Neoplasms.ts\u003cbr\u003eNext Questions- T-Cell Lymphoma.ts\u003cbr\u003eNon BCR-ABL Mutations in CML – Do They Matter..ts\u003cbr\u003eNon-Intensive Treatment of Elderly Unfit Patients With AML.ts\u003cbr\u003eNovel Agents in CLL.ts\u003cbr\u003eNovel Chemotherapy Can Eliminate the Need for Transplant in ALL.ts\u003cbr\u003eNovel Therapeutics in Development for Myelofibrosis.ts\u003cbr\u003eNovel Therapies for Eosinophilia.ts\u003cbr\u003eNovel Therapies for ET.ts\u003cbr\u003eNovel Therapies for PV.ts\u003cbr\u003eNovel Treatment Approaches in Relapsed Refractory PTCL.ts\u003cbr\u003eOrca-T Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies.ts\u003cbr\u003eOutcomes of MM Pts Progressing After BCMA-Targeted CAR T-Cell Therapy.ts\u003cbr\u003ePACE and OPTIC Trials – Dose Modification Dynamics of Ponatinib in CP-CML.ts\u003cbr\u003ePhase 1 2 BRUIN Study – Updated Results on Pirtobrutinib in Previously Treated MCL.ts\u003cbr\u003ePhase II Study of Blinatumomab in Combination With Ponatinib in Ph+ ALL – Updated Results.ts\u003cbr\u003ePivotal Results From a Phase I II Study of Mosunetuzumab Monotherapy for Patients With RR FL Who Have Received ò2 Prior Lines of Therapy.ts\u003cbr\u003eResults from POLARIX, a Phase III Study of Pola-R-CHP vs. R-CHOP Therapy in Patients With Previously Untreated DLBCL.ts\u003cbr\u003eRole of ddPCR in CML Today.ts\u003cbr\u003eRusfertide Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Is Observed in Patients With Polycythemia Vera.ts\u003cbr\u003eSequencing Agents in Early Relapsed MM.ts\u003cbr\u003eSequencing BCMA Targeted Agents in MM.ts\u003cbr\u003eSequencing Novel Agents in Frontline and Second-Line Treatment of Hodgkin Lymphoma.ts\u003cbr\u003eSequencing Therapy in Indolent Lymphoma – Treatment Choices.ts\u003cbr\u003eState of the Art in CML.ts\u003cbr\u003eSupportive Therapy in CLL.ts\u003cbr\u003eTargeted Approaches in MDS.ts\u003cbr\u003eThe Emerging Potential of Bispecific Antibodies as Monotherapy and in Combination for Aggressive B-Cell Lymphoma.ts\u003cbr\u003eThe Next Generation of Novel Agents in Development for Aggressive B-Cell Lymphoma.ts\u003cbr\u003eThe Next Rational Therapeutic Regimen in Newly Diagnosed PTCL.ts\u003cbr\u003eThe Role of Targeted Therapies in Frontline Treatment of MCL.ts\u003cbr\u003eTransplant in MDS.ts\u003cbr\u003eTreating Hodgkin Lymphoma After Brentuximab Vedotin and Anti-PD1 Failure.ts\u003cbr\u003eTreatment of Aggressive B-cell Lymphoma Post-CAR T-Cell Therapy.ts\u003cbr\u003eUpdate on CD47 Targeting Antibodies.ts\u003cbr\u003eUsing Biology to Determine Type and Duration of Treatment in Waldenstrom Macroglobulinemia.ts\u003cbr\u003eWhat Is the Best Strategy for Therapy-Related AML.ts\u003cbr\u003eWhat Is the Role of Transplantation for FL in the Era of CAR T-cell Therapy.ts\u003cbr\u003eWhat’s Next in Aggressive B-Cell Lymphoma.ts\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954479894626,"sku":"MED-AMB04186","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Society-of-Hematologic-Oncology-Tenth-Annual-Meeting-2022.png?v=1779377571","url":"https:\/\/meducourse.com\/products\/society-of-hematologic-oncology-tenth-annual-meeting-2022","provider":"Meducourse","version":"1.0","type":"link"}